Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A|Communicable Diseases|Hepatitis C
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GS-US-337-1512 | P2 |
Completed |
Communicable Diseases|Hepatitis C |
2015-02-01 |
|
2010-023952-10 | P2 |
Terminated |
Hepatitis C, Chronic |
2013-08-15 |
|
2011-002748-28 | P2 |
Completed |
Hepatitis C, Chronic |
2013-07-29 |
|
2011-000456-42 | P2 |
Completed |
Hepatitis C |
2013-06-14 |